摘要
Abstract
OBJECTIVE:To probe into the the clinical efficacy of Tongfuqingqiao decotion combined with Dengzhanxixin injections in treatment of acute cerebral infarction patients and effects on platelet CD62p,TNF-αand IL-6.METHODS:78 patients with cerebral infarction admitted into Hongqi Hospital Affiliated to Mudanjiang Medical College in 2015 were extracted to be divided into control group(odd number) and observation group(even number) via the admission sequence,with 39 cases in each.The control group was given Dengzhanxixin injections,while the observation group additionally received Tongfuqingqiao decotion based on the control group,two weeks were set as one treatment course,two groups both lasted for one course of treatment.The clinical efficacy,safety,and change of platelet CD62p,TNF-αand IL-6 of two groups were compared and observed.RESULTS:After treatment,the clinical symptoms of two groups had been improved significantly compared with before treatment,the total effective rate of observation group was 89.74% (35/39),significantly higher than that of control group [71.79% (28/39)],with statistically significant difference (P < 0.05).Before treatment,there was no statistical significance between two groups in the level of platelet CD62p,TNF-α and IL-6 (P > 0.05).After treatment,the level of platelet CD62p,TNF-α and IL-6 decreased significantly,and the decent in observation group was more obvious than that in control group,with statistically significant difference (P < O.05).CONCLUSIONS:The efficacy of Tongfuqingqiao decotion combined with Dengzhanxixin injections in treatment of acute cerebral infarction patients is effective,which can obviously alleviate the clinical symptoms,promote neurological recovery;and the mechanism may be related with the down-regulation expression of platelet CD62,reducing of the immune response and inflammatory lesions of the central nervous system mediated by cytokines.关键词
通腑清窍汤/急性脑梗死/血小板活化依赖性颗粒表面膜蛋白/肿瘤坏死因子α/白细胞介素6Key words
Tongfuqingqiao decotion/Acute cerebral infarction/CD62p/TNF-α/IL-6分类
医药卫生